Prognostic value of matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9) and aminopeptidase N/CD13 in breast cancer patients

Abstract

The aim of this study was to analyse the expression of matrix metalloproteinase-2(MMP-2), matrix metalloproteinase-9 (MMP-9) and aminopeptidase APN/CD13 in breast carcinoma samples, and their possible prognostic value in breast cancer patients. The expression of MMP-2, MMP-9 and APN/CD13 in tumor cells was analysed in 138 breast carcinomas by immunohistochemical staining of tumor cells using the semiquantitative method for the detection of cytoplasmic and membrane reaction in tumor cells as well as stromal cells positivity. MMP-2 was positive in tumor cells of 52.9% patients and in stromal cells of 74.6% patients, while MMP-9 positive tumor and stromal cells were found in 84.8 and 63.8% patients, respectively. Tumor cell APN/CD13 expression was found in 36.2% patients. Stromal cell MMP-2 expression correlated significantly with tumor size and neoangiogenesis. A positive correlation was also observed between tumor cell MMP-9 expression and hormone receptor status. Stromal cell coexpression of MMP-2/MMP-9 correlated significantly with tumor size. APN/CD13 expression in tumor cells significantly correlated with tumor type and neoangiogenesis. Overall survival was significantly shorter in patients with MMP-2, MMP-2/MMP-9 positive tumor cells, and tended to be shorter in patients with APN/CD13 positive tumor cells. Coexpression of MMP-2/MMP-9 in tumor cells was an independent risk factor for patient survival (OD = 13.9). Our results suggest that MMP-2, MMP-9, APN/CD13 expression and MMP-2/MMP-9 coexpression in combination with other standard prognostic factors can serve as a poor prognostic factor in the evaluation of breast cancer prognosis.

Prognostic Value of Matrix Metalloproteinase 9 Expression in Breast Cancer Patients: A Meta-analysis

“…The remaining 29 papers were approved through scrutinizing the entire paper. Among the 29 papers, five literatures had no sufficient data to analyze (Remacle et al, 1998;Wang et al, 2002;Casar et al, 2010;Mohammad et al, 2012;Ranogajec et al, 2012). MMP-9 protein expression was measured in serum in five studies (Lepp et al, 2004;Lepp et al, 2005;Mattilaet al, 2005;Quaranta et al, 2007;Sung et al, 2012) and one study measured MMP-9 expression in plasma (Ranuncolo et al, 2003).…”

“…Both tumor cell and stromal tissues in breast cancer tissue have been reported to have increased MMP-9 expression (Ranogajec et al, 2012). A considerable number of studies have proved that high MMP-9 expression is related to tumor stage and lymph node metastasis in breast cancer patients (Hanemaaijer et al, 2000;Hao et al, 2007;Gu et al, 2009).…”

Worse prognosis in breast cancer patients can be predicted by immunohistochemical analysis of positive MMP-2 and negative estrogen and progesterone receptors

“…Additionally, both DFS and OS were worse in the presence of MMP-2 and absence of ER (p=0.012 and p=0.005, respectively) ( Figure 2 C and D). Ranogajec et al (2012) studied MMP-2 in breast cancer, and OS was significantly shorter in patients with positive MMP-2. 24 Recently, Min et al 17 correlated the MMP-2 expression pattern with ER and PR, but did not show a correlation with DFS or OS.…”

“…Ranogajec et al (2012) studied MMP-2 in breast cancer, and OS was significantly shorter in patients with positive MMP-2. 24 Recently, Min et al 17 correlated the MMP-2 expression pattern with ER and PR, but did not show a correlation with DFS or OS. In another study that used single nucleotide polymorphism analysis (SNP), the authors suggest that MMP-2 can influence patient survival as an independent factor, attenuating the metastatic potential and augmenting survival rates.…”

Preoperative Serum Levels of Matrix Metalloproteinase-2 (MMP-2) and Survival of Breast Cancer among Korean Women

“…In breast cancer, several studies have found that MMP-2 expression in tumor cells was associated with shortened disease-free survival (DFS), recurrence-free survival (RFS), or overall survival (OS; refs. [19][20][21][22][23], whereas few others have suggested inconsistent results (24,25). Although there were several studies on the association between the levels of serum MMP-2 and clinicopathologic factors, the results were inconsistent across the studies (26)(27)(28)(29)(30)(31)(32)(33)(34)(35).…”